257 related articles for article (PubMed ID: 23638068)
1. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
2. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
3. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
4. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
6. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
7. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
[TBL] [Abstract][Full Text] [Related]
10. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
[TBL] [Abstract][Full Text] [Related]
11. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
13. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
14. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
Petry FR; Pelletier J; Bretteville A; Morin F; Calon F; Hébert SS; Whittington RA; Planel E
PLoS One; 2014; 9(5):e94251. PubMed ID: 24788298
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
[TBL] [Abstract][Full Text] [Related]
16. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
17. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
[TBL] [Abstract][Full Text] [Related]
18. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.
Collin L; Bohrmann B; Göpfert U; Oroszlan-Szovik K; Ozmen L; Grüninger F
Brain; 2014 Oct; 137(Pt 10):2834-46. PubMed ID: 25085375
[TBL] [Abstract][Full Text] [Related]
19. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
20. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
